ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

Post author:admERY
Post published:July 20, 2015
Post category:Newsroom

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

You Might Also Like

ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer

ERYTECH Reports Business and Financial Update for the First Half of 2016

ERYTECH to Host on May 7, 2020 First Quarter Conference Call and Business Update